NCT04470804View on ClinicalTrials.gov

Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

July 30, 2022

Study Completion Date

July 31, 2022

Conditions
Pure Red Cell Aplasia, Acquired
Interventions
DRUG

Sirolimus

Sirolimus treats in experimental group

DRUG

Cyclosporine A

Cyclosporine A uses for active comparator group.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Bing Han

OTHER

NCT04470804 - Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA | Biotech Hunter | Biotech Hunter